Clinical Trial

Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer

Study acronym: NADIA
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study for which participation is requested is a phase II clinical trial to assess the efficacy of dostarlimab as neoadjuvant therapy in patients with MMRd/MSI-H stage II-III endometrial cancer. The study is conducted in Spain with an estimated number of 25 patients for phase II. The main objective of this phase-II study is to evaluate the clinical complete response (cCR) after neoadjuvant therapy with dostarlimab.
Trial Details
NCT Number NCT07013851
Lead Sponsor Grupo Español de Investigación en Cáncer de Ovario
Collaborators: GlaxoSmithKline
Conditions MMRd/MSI-H Stage II-III Endometrial Cancer
Enrollment 25 participants
Start Date 2025-10-01
Primary Completion 2029-03-01 (estimated)
Study Completion 2029-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-06-10